4//SEC Filing
Bradshaw Curt 4
Accession 0001209191-20-060047
CIK 0000879407other
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 5:58 PM ET
Size
7.5 KB
Accession
0001209191-20-060047
Insider Transaction Report
Form 4
Bradshaw Curt
Chief Scientific Officer
Transactions
- Sale
Common Stock
2020-11-19$69.39/sh−15,625$1,084,219→ 15,625 total - Sale
Common Stock
2020-11-20$68.73/sh−15,625$1,073,906→ 0 total
Footnotes (3)
- [F1]Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.
- [F2]The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.16 to $69.06, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F3]93,750 restricted stock units previously reported have been removed from this amount of securities beneficially owned due to forfeiture.
Documents
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
CIK 0000879407
Entity typeother
Related Parties
1- filerCIK 0001794633
Filing Metadata
- Form type
- 4
- Filed
- Nov 22, 7:00 PM ET
- Accepted
- Nov 23, 5:58 PM ET
- Size
- 7.5 KB